Publication: Impact of anemia on clinical outcomes of patients with atrial fibrillation: The COOL-AF registry
Issued Date
2021-03-01
Resource Type
ISSN
19328737
01609289
01609289
Other identifier(s)
2-s2.0-85100481608
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Cardiology. Vol.44, No.3 (2021), 415-423
Suggested Citation
Rungroj Krittayaphong, Satchana Pumprueg, Tomon Thongsri, Weerapan Wiwatworapan, Thaworn Choochunklin, Pontawee Kaewkumdee, Ahthit Yindeengam Impact of anemia on clinical outcomes of patients with atrial fibrillation: The COOL-AF registry. Clinical Cardiology. Vol.44, No.3 (2021), 415-423. doi:10.1002/clc.23559 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78406
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Impact of anemia on clinical outcomes of patients with atrial fibrillation: The COOL-AF registry
Other Contributor(s)
Abstract
Background: To determine whether anemia is an independent risk factor for ischemic stroke and major bleeding in patients with non-valvular atrial fibrillation (NVAF). Hypothesis: Anemia in patients with NVAF increase risk of clinical complications related to atrial fibrillation. Methods: We conducted a prospective multicenter registry of patients with NVAF in Thailand. Demographic data, medical history, comorbid conditions, laboratory data, and medications were collected and recorded, and patients were followed-up every 6 months. The outcome measurements were ischemic stroke or transient ischemic attack (TIA), major bleeding, heart failure (HF), and death. All events were adjudicated by the study team. We analyzed whether anemia is a risk factor for clinical outcomes with and without adjusting for confounders. Results: There were a total of 1562 patients. The average age of subjects was 68.3 ± 11.5 years, and 57.7% were male. The mean hemoglobin level was 13.2 ± 1.8 g/dL. Anemia was demonstrated in 518 (33.16%) patients. The average follow-up duration was 25.8 ± 10.5 months. The rate of ischemic stroke/TIA, major bleeding, HF, and death was 2.9%, 4.9%, 1.8%, 8.6%, and 9.2%, respectively. Anemia significantly increased the risk of these outcomes with a hazard ratio of 2.2, 3.2, 2.9, 1.9, and 2.8, respectively. Oral anticoagulants (OAC) was prescribed in 74.8%; warfarin accounts for 89.9% of OAC. After adjusting for potential confounders, anemia remained a significant predictor of major bleeding, heart failure, and death, but not for ischemic stroke/TIA. Conclusion: Anemia was found to be an independent risk factor for major bleeding, heart failure, and death in patients with NVAF.